Research & Development
Pathology & AI
Biosensors: Page 2
GBS to acquire drug screening firm Intelligent Fingerprinting
The acquisition would enable the combination of Intelligent Fingerprinting's sweat-based drug screening technology with the GBS saliva-based glucose biosensor platform and manufacturing expertise, GBS said.
June 15, 2022
Nicoya completes purchase of LSK Technologies
The deal will allow both firms to improve access to laboratory-quality testing for a variety of indications, Nicoya said.
May 1, 2022
Compact biosensor can detect CSF leaks at the point of care
The new test design, which uses a single-use sensor strip that is inserted into a circuit board with a four-digit readout, resembles a handheld glucometer and is powered by a 9-volt battery. The new device is faster and more sensitive than conventional methods for detecting CSF leaks, which typically require a clinical laboratory, can take hours or days to return results, and often fail to identify the specific leak site, according to the paper's authors, led by Minghan Xian of the University of Florida.
January 31, 2022
New biosensor aids early diagnosis of breast cancer
In a study published in ACS Sensors, a research team led by Dr. Ramón Martínez Máñez from Valencia Polytechnic University noted that mammography is the gold standard for breast cancer detection, but radiation and lower sensitivity and specificity in young women with dense breast tissue are drawbacks to the imaging technology.
May 20, 2021
Protein biosensors show promise for SARS-CoV-2 testing
Biosensors are devices used to detect the presence or concentration of specific biomolecules or biological structures. In this case, the researchers designed protein-based biosensors that recognize specific molecules on the surface of a particular virus and bind to them, then emit light through a biochemical reaction.
January 31, 2021
New assay offers rapid SARS-CoV-2 antibody testing
A team led by Rebecca DuBois, PhD, of the University of California, Santa Cruz developed the method, called biolayer interferometry immunosorbent assay (BLI-ISA), as an alternative to the traditional enzyme-linked immunosorbent assay (ELISA) that takes four to six hours to run. Biolayer interferometry measures interactions between molecules by identifying how molecules bind to the tip of a fiber-optic biosensor.
December 9, 2020
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Aspira announces commercial launch of blood-based ovarian cancer risk assay
Sherlock Biosciences secures funding to further develop CRISPR testing platform
Page 2 of 2